|Day's Range||32.110 - 32.290|
|52 Week Range||29.830 - 37.390|
|PE Ratio (TTM)||27.44|
|Dividend & Yield||1.28 (3.98%)|
|1y Target Est||N/A|
Total prescriptions of Pfizer's eczema drug Eucrisa have flattened out over recent weeks as Regeneron and Sanofi's Dupixent has picked up steam.
The quest has seemed so elusive that it regularly draws comparison to the Holy Grail and unicorns.
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.